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Cytoplasmic TAF2–TAF8–TAF10 complex provides
evidence for nuclear holo–TFIID assembly from
preformed submodules
Simon Trowitzsch1,2, Cristina Viola1,2, Elisabeth Scheer3, Sascha Conic3, Virginie Chavant4, Marjorie Fournier3,
Gabor Papai5, Ima-Obong Ebong6, Christiane Schafﬁtzel1,2, Juan Zou7, Matthias Haffke1,2, Juri Rappsilber7,8,
Carol V. Robinson6, Patrick Schultz5, Laszlo Tora3 & Imre Berger1,2,9
General transcription factor TFIID is a cornerstone of RNA polymerase II transcription
initiation in eukaryotic cells. How human TFIID—a megadalton-sized multiprotein complex
composed of the TATA-binding protein (TBP) and 13 TBP-associated factors (TAFs)—
assembles into a functional transcription factor is poorly understood. Here we describe a
heterotrimeric TFIID subcomplex consisting of the TAF2, TAF8 and TAF10 proteins, which
assembles in the cytoplasm. Using native mass spectrometry, we deﬁne the interactions
between the TAFs and uncover a central role for TAF8 in nucleating the complex. X-ray
crystallography reveals a non-canonical arrangement of the TAF8–TAF10 histone fold
domains. TAF2 binds to multiple motifs within the TAF8 C-terminal region, and these
interactions dictate TAF2 incorporation into a core–TFIID complex that exists in the nucleus.
Our results provide evidence for a stepwise assembly pathway of nuclear holo–TFIID,
regulated by nuclear import of preformed cytoplasmic submodules.
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E
ukaryotic class II gene transcription is controlled by a
plethora of proteins, which are preassembled in large
multiprotein complexes, including RNA polymerase II,
Mediator and the general transcription factors (GTFs)1. The
sequential nucleation of GTFs and Mediator on core promoter
DNA initiates regulated class II gene transcription2. The GTF
TFIID plays a central role in this process by linking cellular
signalling events with regulatory DNA elements and the
transcription machinery3. Although a basal transcription system
supporting initiation of transcription from TATA-box-containing
promoters can be reconstituted with TATA-binding protein
(TBP), TFIIA, TFIIB, TFIIE, TFIIF and TFIIH in vitro, TFIID is
additionally required to respond to activators and for efﬁcient
transcription from TATA-less promoters4,5. In mammalian cells,
most of the expressed protein-coding gene promoters are
occupied by TFIID and loss of TFIID components leads to
embryonic lethality6–9. TFIID subunits are implicated in crosstalk
with epigenetic modiﬁcations on nucleosomes and regulatory
DNA elements in promoter regions10,11. Structural analysis of
TFIID by cryo-electron microscopy revealed the overall
architecture of TFIID and provided important insights into
subunit assembly and promoter recognition at low to medium
resolution12–16.
Canonical human TFIID consists of TBP and 13 TBP-
associated factors (TAFs)17. Other non-canonical TFIID and
TAF-containing complexes have been identiﬁed recently with key
roles during spermatogenesis and stem cell development18–20. A
central scaffold of canonical TFIID comprises two copies each of
TAF4, 5, 6, 9 and 12, which were shown to form a symmetric
core12,21. This core–TFIID complex was ﬁrst identiﬁed in
Drosophila melanogaster nuclei21. TAF3, 4, 6, 8, 9, 10, 11, 12 and
13 contain histone fold domains (HFDs), which stabilize discrete
heterodimers (TAF3–10, TAF4–12, TAF6–9, TAF8–10 and
TAF11–13) (refs 22–25). Among these HFD pairs, the TAF8–10
heterodimer plays a key role in the TFIID assembly pathway, is
critical for the integrity of holo–TFIID and also fulﬁlls essential
functions in early embryonic development6,8,26,27. Binding of
TAF8–10 to core–TFIID triggers a transition from symmetry to
asymmetry, which was proposed to prime the recruitment of
TAF1, 2, 3, 7, 11, 13 and TBP to complete holo–TFIID12.
Evidence from genetic and biochemical studies showed that
knockout of the TAF10 gene leads to impairment of mature
TFIID assembly in F9 EC cells and to dissociation of TFIID in
hepatocytes6,26,27. Biochemical data suggested that TAF8 and
TAF10 interact strongly and speciﬁcally with each other via their
HFDs28. Identiﬁcation of human TAF8 uncovered high sequence
similarities with the Drosophila protein PRODOS and the mouse
TBN protein8,28,29. Mouse embryos carrying a mutation in TBN
develop normally to the blastocyst stage but fail to develop further
due to the lack of inner cell mass cells8. Interestingly, the same
phenotype was also found in TAF10-knockout mice strongly
suggesting that TAF8 and TAF10 are both involved in controlling
embryonic development at similar stages6. The importance of this
cooperative activity of TAF8 and TAF10 is supported by nuclear
import assays, which showed that the transport of TAF10 from
the cytoplasm to the nucleus depends on the nuclear localization
signal (NLS) found at the carboxyl-terminal (C-terminal) end of
TAF8 (ref. 30).
Human TAF2 (originally called either CIF150 or TAFII150) has
been previously described as an essential cofactor for TFIID-
dependent transcription from promoters with initiator (Inr)-
containing promoter elements31–33. Later it was suggested that a
trimeric TBP–TAF1–TAF2 complex is minimally required for
efﬁcient utilization of the Inr and downstream promoter
elements11. TFIID complexes containing or lacking TAF2 have
been described31,34 further suggesting that different types of
TFIID complexes may exist in human cell nuclei. Recently,
mutations in the TAF2-coding gene were shown to be associated
with various neurological disorders35,36. Human TAF2 is
predicted to adopt an aminopeptidase-like fold with an
additional C-terminal unstructured region. Localization studies
using immunopuriﬁed TFIID showed that TAF2 is an integral
part of the central lobe of the holo-complex13.
While general functions of individual TFIID subunits and the
holo-complex are increasingly better understood, very little is
known to date about how the cell assembles this essential
multiprotein complex. The existence of physiological core–TFIID
in the nucleus, containing a subset of TAFs, provides evidence
that the holo-complex may be assembled in a regulated manner
from stable, preformed partial TFIID subassemblies. The
dependence of some of the TAFs on each other for nuclear
import and the critical role of the TAF8–10 pair in functional
remodelling of core–TFIID imply that discrete submodules
preassemble also in the cytoplasm of cells. However, direct
evidence for the presence of subassemblies in the cytoplasm is
lacking to date.
By immunoprecipitating TAF-containing complexes from
different cellular compartments, we identify a novel endogenous
TFIID subcomplex formed by TAF2, 8 and 10 in the cytoplasm of
human cells. We dissect cytoplasmic TAF2–8–10 biochemically
and structurally. We elucidate the interactions that stabilize the
complex and reveal a central role of TAF8 in its nucleation. By
X-ray crystallography, we demonstrate a non-canonical histone-
fold domain pair arrangement between TAF8 and TAF10. We
report a novel interaction between TAF8 and TAF2, mediated by
multiple peptide motifs in the TAF8 C-terminal region. More-
over, we describe the formation of a putative nuclear import
particle comprising the TAF2–8–10 complex and Importin a1.
Furthermore, we demonstrate that the TAF2–TAF8 interaction is
not only crucial for formation of the cytoplasmic TAF2–8–10
complex, but also dictates incorporation of TAF2 into a
physiological core–TFIID complex that exists in the nucleus.
Results
An endogenous cytoplasmic TAF2–8–10 complex. With the
objective to better understand human TFIID assembly and in
particular the incorporation of TAFs into holo–TFIID, we carried
out immunoprecipitations from HeLa cell cytoplasmic and
nuclear extracts. To test the role of TAF2 in the assembly process,
we raised a polyclonal antibody using highly puriﬁed recombi-
nant human TAF2 protein for the immunization procedure. We
ascertained speciﬁcity of the puriﬁed antibody against recombi-
nant TAF2 and endogenous TFIID by western blotting (Fig. 1a
and Supplementary Fig. 1a). Using this antibody, we carried out
co-immunoprecipitation experiments of endogenous TAF2 from
the cytoplasm, where TAF2 is synthesized de novo, and from
nuclear extracts, where TAF2 likely functions in the context of
TFIID. To identify proteins that co-precipitated with TAF2 we
subjected the immunoprecipitated samples to proteomics analysis
by using the multidimensional protein identiﬁcation technology
(MudPIT). MudPIT analysis of proteins co-precipitated with
TAF2 from the nuclear fraction revealed the full set of TFIID
components (Fig. 1b and Supplementary Table 1). We observed
differences in abundance of the individual TAFs, which may
argue for the presence of distinct TAF2-associated TAF or TFIID-
like complexes in the nucleus. Strikingly, MudPIT analysis of
TAF2-associated proteins from the cytoplasmic fraction identiﬁed
only TAF8 and TAF10, whereas none of the other TAFs could be
detected (Fig. 1b,c). We conﬁrmed the presence of TAF2, TAF8
and TAF10 in the cytoplasm of HeLa cells by immuno-
ﬂuorescence experiments (Fig. 1d,e and Supplementary Fig. 1b).
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These data suggest that a unique endogenous TAF2–TAF8–
TAF10-containing TFIID building block exists in the cytoplasm.
TAF8 nucleates the TAF2–8–10 complex. To further analyse
this TAF2–TAF8–TAF10 complex, we used highly puriﬁed
recombinant human TAF2, TAF8 and TAF10 to reconstitute
TAF2–8–10 in vitro. We produced recombinant TAF2 and the
TAF8–10 pair separately in insect cells and tested complex for-
mation by size-exclusion chromatography (SEC) experiments.
SEC of a stoichiometric mixture of TAF2 and TAF8–10 showed a
clear peak shift in retention volume towards earlier fractions as
compared with the individual components (Fig. 2a). Analysis of
the chromatographic fractions by SDS-polyacrylamide gel elec-
trophoresis (SDS–PAGE) shows that all three polypeptides co-
elute in the same fractions (Fig. 2a). We observed unusually high
molecular weight estimates for the components TAF2 and TAF8–
10, and also for the complete TAF2–8–10 complex, which exceed
the calculated molecular weights of the proteins. These high
estimates can be due to either oligomerization or elongated
shapes of the specimens analysed. We therefore determined the
oligomeric states of puriﬁed TAF2, TAF8–10 and the TAF2–8–10
complex by analytical ultracentrifugation sedimentation velocity
and native mass spectrometry (MS) experiments. Sedimentation
coefﬁcients of 4.3 S, 2.3 S and 4.9 S were obtained for TAF2,
TAF8–10 and TAF2–8–10, respectively (Fig. 2b). Continuous
size-distribution analyses returned best-ﬁt molecular weights of
140, 52 and 200 kDa. These values are in good agreement with
monomeric TAF2, heterodimeric TAF8–10 and heterotrimeric
TAF2–8–10 complexes, with subunit stoichiometries of 1:1 and
1:1:1 in case of the complexes.
Analysis of TAF2–8–10 by native MS revealed a predominant
complex with an average molecular mass of 195,797Da
corresponding to a TAF2–8–10 heterotrimer containing one
copy of each protein (Supplementary Fig. 2a and Supplementary
Table 2). We subjected the TAF2–8–10 complex to collision-
induced dissociation (CID) experiments in the mass spectrometer
to probe for subunit interactions37. The resulting spectra reveal
dissociation of the trimeric complex into TAF2–8 and TAF10
submodules (Fig. 2c and Supplementary Table 2). Notably, TAF2
and TAF10 do not interact under the conditions studied, since we
did not observe a TAF2-10 species (Fig. 2c). We conclude from
these data that TAF2, 8 and 10 assemble as a heterotrimeric
complex with a 1:1:1 stoichiometry and that the complex is
nucleated by TAF8 and stabilized by distinct TAF2–8 and TAF8–
10 interactions.
TAF8 and TAF10 adopt a non-canonical histone fold dimer.
We next dissected the interactions identiﬁed by CID. First, we
determined the X-ray crystal structure of the TAF8–10 complex.
Previous GST pull-down experiments suggested that the inter-
action between TAF8 and TAF10 is mediated by their HFDs,
which are present in the amino-terminal (N-terminal) half of
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Figure 1 | ATAF2–8–10 complex exists in the cytoplasm. (a) Puriﬁed, polyclonal anti-TAF2 antibodies speciﬁcally recognize recombinant and endogenous
TAF2. Recombinant (rec.) puriﬁed TAF2 (10 ng, lane 1) and immunopuriﬁed TFIID (300 and 150 ng; lanes 2, 3) were loaded on an 8% SDS–PAGE, blotted
and analysed by western blot assay. Protein size markers are indicated. (b) Abundances of individual proteins co-immunoprecipitated from nuclear or
cytoplasmic HeLa cell extracts (grey or black bars, respectively) using puriﬁed polyclonal anti-TAF2 antibodies were compared in units of normalized
spectral abundance factors (NSAFs). Each column is the average of two independent experiments and error bars represent range of the data. (c) Domain
organization of TAF2, TAF8 and TAF10 in a schematic view. Grey rectangles indicate predicted, unstructured regions. The NLS of TAF8 is shown as a black
bar. Numbers indicate ﬁrst and last amino acids in each protein. (d) Immunoﬂuorescence microscopy of HeLa cells. Nuclei are visualized by 40 ,6-diamidino-
2-phenylindole (DAPI) staining (blue). TAF2 is displayed in green and TAF8 in red. The bottom panel shows images of control cells, which were treated
with secondary antibodies only. Scale bar, 10 mm. (e) Immunoﬂuorescence microscopy of HeLa cells as in d, but displaying TAF2 (green) and TAF10 (red).
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TAF8 and the C-terminal half of TAF10 (refs 28,30). We co-
expressed and puriﬁed full-length TAF8–10 complex in insect
cells from a polyprotein construct38, subjected the complex to
limited proteolysis and deﬁned the core complex to TAF8
residues 1–134 and TAF10 residues 98–218 (hereafter referred to
as TAF8DC and TAF10DN, respectively; Supplementary Fig. 3a).
We prepared this TAF8DC–TAF10DN core complex, but only
obtained crystals diffracting X-rays to 5–6Å resolution. We
therefore tested various N- and C-terminal deletion constructs of
the two proteins in crystallization experiments. A complex of
TAF8–10 comprising TAF8 residues 25–120 and TAF10 residues
112–212 yielded crystals, which diffracted incident X-rays to
1.9 Å resolution (Supplementary Fig. 3b). We determined the
structure of this complex by the Sulfur-SAD method and reﬁned
the model to a crystallographic R value of 20.5% and a free R
factor of 23.7% with excellent stereochemistry (Table 1). The ﬁnal
model includes TAF8 residues 28–120 and TAF10 residues
113–212 with the exception of a ﬂexible loop in TAF10
comprising residues 178–191.
The crystal structure of the TAF8–10 complex reveals that the
two proteins adopt atypical HFDs with three central a helices
ﬂanked by additional N- and C-terminal a helices (Fig. 3a). In
our structure, TAF8 wraps entirely around the a2 helix of
TAF10 markedly enveloping its interaction partner (Fig. 3a).
Complex formation buries 2212.3 Å2 with predominantly
hydrophobic intermolecular contacts. As observed in other
HFD interactions, the two opposing aromatic residues Y68 of
TAF8 and F162 of TAF10 at the crossover of the a2 helices
contact each other via hydrophobic stacking interactions
and categorize the complex to the H3/H4 family of HFD-
containing proteins (Fig. 3b and Supplementary Fig. 3c)39.
The additional N-terminal a-helix of TAF10, aN and the
C-terminal a-helix of TAF8, aC, contact each other on one side
of the HFD in a head-to-tail fashion and signiﬁcantly stabilize
the complex by hydrophobic interactions centred on F119 of
TAF10 (Fig. 3c).
Interestingly, the proteins TAF8 and TAF10 have similar L1
loop geometries, which are not found in other structures of
related HFD-containing TAFs (Fig. 3d,e)22,25. In both proteins, a
phenylalanine of loop L1 (F50 in TAF8 and F144 in TAF10) is
embedded in a composite, hydrophobic cavity mainly formed by
residues from helices a1/a2 of one protomer and helices a2/a3 of
the other (Fig. 3d,e). The amino acids forming this hydrophobic
cavity are remarkably similar in TAF8 and TAF10, suggesting an
evolutionary interrelation between the two proteins (Supple-
mentary Fig. 3d). To test the functionality of the TAF10 HFD and
chimeric mutants thereof, we performed complementation assays
in TAF10 null mouse F9 cells40. Interestingly, the human TAF10
HFD (residues 116–218) is fully functional in the complemen-
tation assay, whereas chimeric constructs, in which either the
N-terminal region of TAF10 (residues 116–150) or the
C-terminal region (residues 151–218) was substituted by
sequences of the yeast TAF10 homologue, were not functional
(Supplementary Fig. 3f,g).
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Primary sequence comparison with two other TAF10-inter-
acting proteins, TAF3 and human SPT7L, shows that similar
residues can be also found in their HFDs30, arguing for a
conserved binding mode of these proteins known to interact with
TAF10 (Supplementary Fig. 3d). Our structure underscores that
HFDs in TAFs can adopt a variety of conformations, which may
differ signiﬁcantly from the canonical histone pairs found in the
nucleosome.
HFDs of TAF8 and TAF10 are dispensable for TAF2 binding.
We next analysed the physical interactions between TAF2
and the TAF8–10 heterodimer. We ﬁrst tested the effects of
deleting the intrinsically unstructured regions of TAF8 and
TAF10 on TAF2 binding in pull-down assays with puriﬁed
proteins. As a control, full-length TAF8–10 was co-precipitated
with TAF2 tagged with maltose-binding protein (MBP;
Fig. 3f). Truncation of the N-terminal region of TAF10
(TAF8–TAF10DN, TAF10 residues 98–218) did not change the
binding properties and still co-precipitated with MBP–TAF2.
In contrast, a truncated complex of TAF8–10, in which the
ﬂexible C-terminal region of TAF8 was deleted (TAF8DC–
TAF10, TAF8 residues 1–134), did not co-precipitate with
MBP–TAF2 suggesting that the region that mediates binding to
TAF2 resides in the C-terminal, low-complexity tail of TAF8
(Fig. 3f). We conﬁrmed the interaction between TAF2 and the
C-terminal tail of TAF8 by SEC. We utilized full-length TAF2
and a fusion protein of MBP with residues 105–310 of TAF8 and
evidenced complex formation (Supplementary Fig. 4). These
results are consistent with the CID data in native MS, which
showed that only TAF8, and not TAF10, is directly interacting
with TAF2.
TAF2 recognizes short motives in the TAF8 C-terminal region.
We characterized the TAF2–TAF8 interaction further by means
of a peptide array. We monitored the binding of His-tagged TAF2
to peptide arrays covering residues 105–310 of TAF8 (Fig. 4a).
Densitometric analysis of the arrays indicated that TAF2-binding
clusters around four distinct regions; a short N-terminal region I
covering TAF8 residues 105–125, a less well-deﬁned region II
including residues 147–202 and regions III and IV spanning
residues 207–238 and 282–310, respectively (Fig. 4a).
We next analysed the individual contributions of these four
TAF8 regions to TAF2 binding by surface plasmon resonance
(SPR) experiments. We generated N- and C-terminal deletion
constructs of TAF8 and fused them to MBP (Fig. 4b). We
monitored the association and dissociation phases of the MBP–
TAF8 truncations on TAF2-charged sensor chips and compared
binding kinetics at identical analyte concentrations. An MBP–
TAF8-fusion construct spanning the entire C-terminal region
(TAF8 residues 105–310) showed a maximal association level of
about 85 response units (RU) with fast on and off rates (Fig. 4b).
A shorter MBP-fusion protein lacking region I (TAF8 residues
141–310) showed similar kinetics but a reduced maximal
association level of B40 RU (Fig. 4b). MBP-fusion constructs
with deleted regions I and II or IV (TAF8 residues 200–310 or
105–260, respectively) hardly interacted with immobilized TAF2
showing maximal association levels of less than 10 RUs (Fig. 4b).
These data indicate that all four TAF2-interacting regions of
TAF8 contribute cooperatively to the binding to TAF2.
On the basis of our peptide array and SPR results, we
introduced TAF8 point mutants into the TAF8–10 polyprotein
expression construct by substituting three triple amino-acid
clusters spanning residues 185–187 (DVE), 222–224 (PYL)
and 293–295 (PYL) with alanines. We produced and puriﬁed
Table 1 | X-ray data collection and reﬁnement statistics.
TAF8–10
Native
TAF8–10
S-SAD
Importin a1/TAF8–NLS
Native
Data collection
Space group P3121 P3121 P212121
Cell dimensions
a, b, c (Å) 51.32, 51.32, 144.40 51.30, 51.30, 144.70 54.27, 77.72, 128.57
a, b, g () 90, 90, 120 90, 90, 120 90, 90, 90
Wavelength 0.98011 1.90745 0.93340
Resolution (Å) 44.44–1.91 (1.98–1.91)* 48.23–2.61 49.54–1.75 (1.81–1.75)
Rmerge 2.92 (87.98) 2.00 5.00 (77.45)
I/sI 23.4 (1.68) 48.43 19.18 (2.03)
Completeness (%) 93.91 (58.53) 100.00 99.60 (99.14)
Redundancy 4.80 (4.30) 20.91 4.60 (4.60)
Reﬁnement
Resolution (Å) 44.44–1.91 49.54–1.75
No. of reﬂections 16,793 (1,630) 12,943 55,423 (5,436)
Rwork/Rfree 20.5 (33.1)/23.7 (35.5) 15.3 (23.9)/18.0 (27.2)
No. of atoms 1,474 3,877
Protein 1,404 3,366
Ligand/ion 7 48
Water 63 463
B-factors
Protein 58.2 30.9
Ligand/ion 59.9 59.6
Water 51.9 44.8
R.m.s. deviations
Bond lengths (Å) 0.003 0.008
Bond angles () 0.681 1.158
R.m.s., root mean squared.
*Values in parentheses are for highest-resolution shell.
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wild-type TAF8–10 and the mutated TAF8–10 complex and
analysed TAF2 binding via SEC (Fig. 4c). In contrast to wild-type
TAF8–10, formation of a trimeric TAF2–8–10 complex was not
observed with the three triple amino-acid cluster TAF8–10
mutant, corroborating the results that we obtained with our
peptide array and SPR experiments (Fig. 4c).
TAF8 promotes TAF2 incorporation in TFIID. We showed
recently that a TFIID subcomplex comprising TAF4, 5, 6, 8, 9, 10
and 12 (hereafter referred as 7TAF) can be formed in vitro by
binding TAF8–10 to a physiological nuclear core–TFIID com-
plex, which constitutes an important intermediate in holo–TFIID
assembly12,21. We next asked whether the association of TAF2 to
this 7TAF complex depends on the C-terminal region of TAF8,
which we identiﬁed as responsible for TAF2 binding in the
TAF2–8–10 complex. We produced and puriﬁed recombinant
7TAF and a 7TAFD complex, in which TAF8 is substituted by
TAF8DC (Fig. 5a). We monitored binding of a mCherry-TAF2
fusion protein to 7TAF and 7TAFD complexes using SEC. We
introduced the mCherry tag on TAF2 to unambiguously separate
the protein from TAF4 in SDS–PAGE. In all SEC experiments, we
used stoichiometric amounts of TAF2 in relation to TAF8–10 or
the truncated TAF8DC–TAF10 complex. Interestingly, TAF2
could be fully incorporated into the 7TAF complex, whereas
TAF2 did not interact noticeably with the 7TAFD complex, in
which the C-terminal TAF2-interaction region of TAF8 had been
deleted (Fig. 5b).
Next we mapped the position of TAF2 on 7TAF. To this end,
we determined a three-dimensional model of negatively stained
7TAF complexes bound to TAF2 (hereafter referred as 8TAF
complex) by single-particle electron microscopy and compared
the resulting structure to the reconstruction of the 7TAF complex
we had determined previously12. We observed major density
differences clearly positioned on only one side of the particle,
indicating TAF2 location (Fig. 5c and Supplementary Fig. 5a).
Interestingly, our 8TAF complex reconstruction resembles a
precursor to the characteristic clamp shape of holo–TFIID, in
contrast to the less elongated shape of 7TAF and core–TFIID10
(Supplementary Fig. 5b).
Next we sought to characterize possible alterations in the
protein–protein interaction networks along the assembly pathway
to holo–TFIID. In particular, we looked at the transition from
7TAF to 8TAF complexes on TAF2 binding by crosslinking and
MS (CLMS) experiments. We crosslinked 7TAF and 8TAF
complexes with the bifunctional reagent bis(sulfosuccinimidyl)-
suberate, BS3 that targets mostly lysines41 (Supplementary
Fig. 6a). Crosslinked complexes were separated from non-
crosslinked species by SDS–PAGE, in-gel digested and
crosslinked peptides were assigned to ion masses observed by
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MS. We identiﬁed 37 protein–protein crosslinks for the 7TAF
complex and 37 protein–protein crosslinks for the 8TAF complex
with an overlap of 21 crosslinked peptides between the two
complexes (Fig. 5d, Supplementary Fig. 6b–e and Supplementary
Table 3). Our data suggest that TAF9 plays a central role in 7TAF
complex architecture by interconnecting TAF4, 5, 6, 8 and 12
(Fig. 5d). In our CLMS data, prominent crosslinks between TAF8
and TAF10 were not present, consistent with the paucity of
lysines within crosslinking distance, and the partly buried
location of the TAF8–10 dimer within the 7TAF complex12.
In the 8TAF complex, we observed crosslinks of the C-terminal
region of TAF8 with residues on TAF2, which are predicted to
map to the surface (Fig. 5d). In addition to its proximity to
TAF8, TAF2 is also positioned closely to TAF5, 6 and 9
TAF2-8-10
12,000
Co
nt
ro
l
H
is
-T
AF
2
l Il IIl IV
8,000
R
el
at
ive
 in
te
ns
ity
4,000
0
A1 B1 B6 C1 C6 D1 E1D6
Spot position
110
I II III IV
310
310
310
310200
260105
HFD
HFD
HFD
HFDMBP
MBP
MBP
MBP
HFDTAF8 1
141
105
R
es
po
ns
e 
un
its
 (R
U) 90
70
50
30
10
0
0 100 200 300 400
Time (s)
Fractions
12
TAF2
TAF8mut
TAF10
TAF2
TAF8mut
TAF10
TAF2
TAF8
TAF10
111097654321INSize (kDa)
150
100
TAF2
Fractions1197531
TAF8mut-10
TAF2
+TAF8mut-10
37
150
100
100
80
Ab
so
rp
tio
n 
un
its 60
40
20
0
75
50
37
150
100
75
50
37
8
500 600 700 800
E6 F1 F6
MBP-TAF8_105–310
MBP-TAF8_141–310
MBP-TAF8_200–310
MBP-TAF8_105–260
MBP
G1 G6A6
1 2 3 4 5 6
A
B
C
D
E
F
G
A
B
C
D
E
F
G
7 8 9 10
1 2 3 4 5 6 7 8 9 10
0.7 0.9 1.1 1.3 1.5
Elution volume (ml)
1.7 1.9
Figure 4 | TAF8–TAF2 interactions. (a) His-tagged TAF2 binding to overlapping peptides of the TAF8 C-terminal region (residues 105–310) spotted onto
nitrocellulose membranes (spots A2-G4, left) was analysed by utilizing a peptide array. Bound TAF2 was visualized by luminol reaction and signal
intensities were plotted for each spot after background subtraction (right). Spots A1, G5 and G6 served as positive controls. TAF2 protein was omitted for
the control membrane. The four major binding regions (I–IV) are indicated above the histogram. (b) SPR experiments with immobilized full-length TAF2 as
ligand and MBP (control) as well as MBP fusions of TAF8 fragments 105–310, 141–310, 200–310 and 105–260 as analytes. TAF8 deletion constructs are
schematically shown as bar diagrams (left). TAF2-interacting regions on TAF8 as identiﬁed in a are highlighted. SPR sensorgrams at identical analyte
concentrations of 500nM are plotted as RU versus time (right). (c) SEC analyses assessing the inﬂuence of TAF8 point mutations on TAF2 binding. Elution
proﬁles for the indicated proteins and protein complexes are plotted on the left and SDS–PAGE analyses of each run are shown on the right. Molecular
masses of protein standards are denoted on the left of the gels and protein names on the right.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7011 ARTICLE
NATURE COMMUNICATIONS | 6:6011 | DOI: 10.1038/ncomms7011 | www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
and promotes crosslinking between TAF4 and 5 (Fig. 5d). Our
data indicate that TAF2 is indeed anchored to the 7TAF
complex via the TAF2-interacting region on TAF8 and that
binding of TAF2 induces signiﬁcant conformational changes
that result in novel TAF–TAF interactions not present in the
7TAF complex.
TAF2–8–10 binds Importin a1 via the TAF8 NLS. Biochemical
and cell biology experiments demonstrated that the C-terminal
NLS within TAF8 is necessary for shuttling TAF8 and TAF10
from the cytoplasm to the nucleus in an Importin a/b-dependent
fashion30. We asked whether the identiﬁed endogenous TAF2–8–
10 complex would be capable of recruiting Importin a1 in vitro to
form a nuclear import complex. To this end, we mixed highly
puriﬁed TAF2–8–10 with a twofold molar excess of an Importin
a1 variant lacking the Importin b-binding domain (Importin
a1DIBB). We observed efﬁcient complex formation in SEC
indicating that Importin a1DIBB was stoichiometrically
incorporated into the TAF2–8–10 complex (Fig. 6a and
Supplementary Fig. 7a). We also observed by SEC that TAF2
alone is not bound by Importin a1.
To deﬁne the binding region between Importin a1 to the
TAF2–8–10 complex, we determined the X-ray crystal structure
of the C-terminal NLS of TAF8 in complex with Importin a1DIBB
at 1.75 Å resolution. The reﬁned model has a crystallographic R
value of 15.3% and a free R factor of 18.0% with good
stereochemistry (Table 1). Importin a1 residues 72–497 and
residues 297–305 of the TAF8 peptide could be unambiguously
traced in the electron density map. The TAF8 peptide binds as a
monopartite NLS via residues 297–302 (Fig. 6b). In previous
Importin/NLS structures, asparagines N146, N188 and N235 of
Importin a1 hydrogen bond to NLS main chain amide and
carbonyl groups at positions P1, P3 and P5 (ref. 42) (Fig. 6b and
Supplementary Fig. 7b). Importin a1 tryptophanes W142, W184
and W231 form apolar pockets, which accommodate the aliphatic
moieties of lysine residues K300 and K302, and position the TAF8
NLS backbone via residues P297, K300 and K302 (Fig. 6b). The
side chain of K299 of TAF8 is coordinated by the main chain
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carbonyl group of G150, the hydroxyl group of T155 and the
carboxylate of D192, whereas side chains of K300 and K302 of
TAF8 are contacted by side chain carbonyl groups of N228 and
Q181, respectively. We could also model a less well-deﬁned short
amino-acid segment at the minor binding site of Importin a1
(Supplementary Fig. 7c). To assess whether the minor binding site
of Importin a1 plays a role in binding the NLS of TAF8, we
determined the kinetic parameters for the Importin a1/TAF8–
NLS complex formation by isothermal titration calorimetry.
Using Importin a1DIBB as an analyte and an NLS peptide
comprising TAF8 residues 288 to 310 as titrant, we obtained a 1:1
binding stoichiometry with a dissociation constant in the low
micromolar range (Kd¼ 10.4þ / 0.8 mM; Supplementary
Fig. 7d). In accordance with our crystal structure, the binding
of the NLS of TAF8 to Importin a1 is driven by enthalpy
involving mainly hydrogen bonds and van der Waals interactions
(enthalpy change of DH¼  18.5þ / 1.3 kcalmol 1 and
entropy change of TDS¼ 11.5 kcalmol 1).
We next asked if the nuclear localization of TAF2 is dependent
on the presence of TAF8 in vivo. Therefore, we knocked down
endogenous TAF8 in HeLa cells by RNA interference (RNAi)
treatment for 48 h and compared the nuclear/cytoplasmic
distribution of TAF2 in TAF8 knockdown cells with control
cells by immunoﬂuorescence (Fig. 6c). Short interfering RNA
(siRNA) treatment leads to depletion of TAF2 in the nucleus and
to an enrichment of TAF2 in the cytoplasm, suggesting that the
import of TAF2 is controlled by TAF8 (Fig. 6c).
Taken together, our data suggest the presence of a nuclear
import particle in which the TAF2–8–10 complex is bound by the
major binding site of Importin a1 via the NLS of TAF8, poised to
shuttle into the nucleus (Fig. 6d). On release of Importin a1, the
TAF2–8–10 module then combines with core–TFIID
(Supplementary Fig. 2b,c). Association of these preformed TFIID
submodules leads to conformational rearrangements in the
resulting intermediate TAF complex which enables formation of
the functional nuclear holo–TFIID (Fig. 6d).
Discussion
Elucidation of the structure and function of multiprotein
complexes in gene regulation is an intense focus of current
research efforts43,44. Whereas three-dimensional models of fully
assembled multiprotein complexes derived from X-ray
crystallography or single-particle cryo-electron microscopy
provide a wealth of information on the architecture of such
complexes, little is known about how the cell controls and
regulates the ordered assembly of multiprotein gene regulatory
complexes such as TFIID.
Several earlier studies described the existence of a variety of
TFIID complexes with distinct subunit composition in different
cell types23,45–48 conveying a concept of modular TFIID
assembly. To gain more insights into the regulated assembly of
TFIID, and to try to understand how the regulated assembly of
such complexes may contribute to gene regulation, we initiated a
series of experiments to identify TFIID assembly intermediates in
the cytoplasm, and different TFIID assemblies in the nuclei of
human cells. In the framework of these experiments, we were also
aiming to uncover the incorporation pathway of TAF2 in
TFIID. We identiﬁed a novel TFIID building block comprising
TAF2–TAF8–TAF10 in the cytoplasm of human cells. We also
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characterized the interactions stabilizing this cytoplasmic
complex in an integrated approach combining native MS, X-ray
crystallography, SPR, peptide arrays and biochemical and
biophysical methods. Our experiments indicate that TAF2
interacts with the C-terminal unstructured region of TAF8
in vitro, substantiating protein–protein interaction mapping
experiments of Saccharomyces cerevisiae TFIID49.
Previously, it was shown that TAF8 shuttles from the
cytoplasm to the nucleus in an Importin a/b-dependent pathway
and piggybacks TAF10 into the nucleus30. Owing to the lack of a
NLS, TAF10 cannot translocate to the nucleus on its own and
depends on the NLS of its interaction partner, TAF8 (ref. 30).
Deletion mutants suggested that Importin binding resides in the
extreme C-terminus of TAF8 (ref. 30). We show that a tetrameric
complex consisting of Importin a1, TAF2, TAF8 and TAF10 can
be assembled from puriﬁed components in vitro suggesting a co-
import mechanism for the three proteins. Our TAF2 and TAF10
cellular localization experiments support this mechanism,
indicating that knockdown of TAF8 by RNAi not only alters
the cellular localization of TAF10, but likewise the localization of
TAF2.
To deﬁne the precise modes of interaction between Importin
a1, TAF8 and TAF10, we solved the X-ray crystal structures of
Importin a1 bound to the NLS of TAF8 on one hand, and of the
HFD pair formed by TAF8 and TAF10 on the other. The crystal
structure of the TAF8–10 complex reveals atypical histone folds
of the two proteins and shows a combination of symmetric and
asymmetric structural elements. Both TAFs share characteristic
conformations of their L1 loops, which give rise to pseudosym-
metric structures at the extremities of their HFDs. Otherwise, the
presence of additional aN and aC helices render the TAF8–10
complex asymmetric. The pseudosymmetric L1 loops are
characteristic for the TAF8–10 complex, since similar arrange-
ments cannot be found in the crystal structures of the Drosophila
TAF6–TAF9 and the human TAF4–TAF12 complex22,25
suggesting that the overall shape and precise geometry of the
complex is important for integration into core–TFIID.
The crystal structure of Importin a1 with the NLS of TAF8
reveals that TAF8 has a classical short monopartite NLS, which is
recognized by the major binding site of Importin a1. Interest-
ingly, phosphorylation of conserved serine residues C-terminal to
canonical NLSs of different nuclear proteins either enhance, or
abolish, the binding afﬁnity of different importins, thus regulating
nuclear import50–52. Similarly, phosphorylation may also ﬁne-
tune nucleocytoplasmic shuttling of the TAF2–8–10 complex.
Two serine residues predicted to be phosphorylated are located
C-terminal to the NLS of TAF8. Therefore, the afﬁnity of TAF8 to
Importin a1 and consequently the nuclear import could be
modiﬁed by phosphorylation. It will be interesting to see if such a
regulatory mechanism by post-translational modiﬁcation exists
for the import of the TAF2–8–10 complex in vivo. Our crystal
structure of Importin a1 bound to the TAF8 NLS further suggests
that the cytosolic TAF2–8–10 complex together with Importin a1
constitutes an import particle responsible for delivering this
building block into the nucleus. Likewise, our experiments
indicate that this TAF2–8–10 building block is responsible for
the incorporation of TAF2 in nuclear TFIID.
A stable TFIID core complex comprising two copies each of
TAF4, 5, 6, 9 and 12 was identiﬁed in Drosophila and human
cell nuclei12,21. Previously, we postulated that the binding of
TAF8–10 causes a rearrangement of the symmetric TFIID core
complex to an asymmetric particle, which is then capable of
accommodating the remaining TAFs and TBP, each in single
copy12. We propose that association of the TAF2–8–10 complex
with the preassembled nuclear core–TFIID involves an intricate
network of interactions between the TAF8 C-terminal tail and
TAF2 on one hand, and the globular HFD pair of the TAF8–10
complex and core–TFIID on the other. Our current data suggest
that TAF8–10 may function alike a chaperone to regulate nuclear
import and integration of TAF2 into core–TFIID. Note, however,
that in the cytoplasmic extracts, apart from TAF8 and TAF10, we
did not detect any of the other TFIID components stably
associated with endogenous TAF2. Therefore, we hypothesize
that TAF1, 7, 11, 13 and TBP incorporate into the TFIID
structure probably at a deﬁned, later step, after TAF2–8–10 has
been accreted. Moreover, notwithstanding the fact that we did not
ﬁnd either TAF1 or TBP associated with TAF2 in the cytoplasm
in our co-IP coupled MS analyses, it still can be envisioned that
the TAF2–8–10 complex is capable of nucleating the formation of
the holo–TFIID complex, including the TAF1–TBP module, and
thus promote transcription from Inr-containing core promoters.
Interestingly, TAF2-containing and TAF2-lacking, as well as
TAF10-containing and TAF10-lacking, TFIID complexes have
also been extracted from human cells32,34,45. Thus, in good
agreement with the modular TFIID assembly concept, our
observations suggest that the here characterized TAF2–8–10
building block would not always incorporate in all canonical
TFIID complexes but, even in the nucleus, may exist as an
independent regulatory entity. Future experiments will be
required to elucidate the function(s) of holo–TFIID complexes
versus complexes lacking TAF2–8–10. Along the same lines, it
will also be interesting to test whether a TAF2–8–10 complex
alone or in combination with core–TFIID can modulate
transcription efﬁciency of Inr-dependent genes. Promoter
architecture may at this junction control transcription
regulation by gauging the assembly rate of holo–TFIID from
building blocks48. From a pharmaceutical point of view, it is to
date entirely unclear whether or not neurological disorders caused
by mutations in the TAF2 gene develop due to altered regulation
of transcriptional activity or due to other currently unknown
mechanisms. Future experiments will be required to elucidate if
these TAF2 mutations may actually affect TAF8 binding and
TFIID assembly.
Our results support the view that stable partial TFIID
complexes—that potentially have important functions of their
own—might exist in the cell. These complexes may represent
functional cytoplasmic or nuclear modules, which assemble into
holo–TFIID in a stepwise fashion. Also, our results point to an
important role of cytoplasmic–nuclear transport in holo–TFIID
formation. We anticipate that such processes will likewise play
important roles in regulating the assembly and activities of many
other multiprotein complexes that direct gene transcription.
Methods
DNA constructs. Cloning of TAF2, TAF8 and TAF10 expression constructs in
MultiBac plasmids pPBac38, pFL and pIDC53 is detailed in the Supplementary
Methods. Expression plasmids for subcomplexes TAF5–6–9 (pPBac-3TAF) and
TAF4–12 (pDiFB-412) and Importin a1DIBB were described previously12,54.
Truncated Importin a1 (residues 71–497) was generated by amplifying the coding
region of Importin a1DIBB by PCR. All constructs were veriﬁed by DNA sequencing.
Sequence alignments. Alignments were generated using the ClustalW2 server55
and plotted with ESPript (http://espript.ibcp.fr)56. Protein sequences for human
TAF3 (UniProt accession number Q5VWG9) and human SPT7L (O94864) were
retrieved from the UniProt server (www.uniprot.org).
Protein production and puriﬁcation. MBP–TAF8-fusion proteins were produced
in E. coli Rosetta (DE3) cells (Novagen) and puriﬁed by metal afﬁnity chromato-
graphy using TALON resin (Clontech) followed by size-exclusion chromatography
on a Superdex 200 16/60 column (GE Healthcare; detailed in Supplementary
Methods). Importin a1 constructs (residues 60–529 or residues 71–497) were
produced and puriﬁed as described54, except that E. coli Rosetta (DE3) cells
(Novagen) were used. Production and puriﬁcation of core–TFIID and 7TAF
complexes was performed as described12.
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Proteins TAF2, MBP–TAF2, mCherry-TAF2 and TAF8–10 complex were
produced using the MultiBac system53. Expressed protein was captured via
TALON resin (Clontech) from the cell lysate in batch. Proteins were further
puriﬁed by ion exchange chromatography using a 5-ml SP-Sepharose HiTrap
column (GE Healthcare) followed by gel ﬁltration using Superdex200 10/300 or
Superose6 10/300 columns (GE Healthcare; Supplementary Methods). Proteins
were ﬂash frozen in liquid nitrogen and stored at  80 C in aliquots.
Binding experiments. SEC experiments were carried out with A¨KTA puriﬁer or
A¨KTA Micro systems (GE Healthcare) using Superdex200 10/300, Superdex200
PC3.2, Superose6 PC3.2 or Superose6 PC3.2 Increase columns. Binding experi-
ments shown in Fig. 2a were performed in running buffer comprising 25mM
HEPES-NaOH, pH 7.5, 150mM NaCl, 1mM DTT (dithiothreitol). Runs in Figs 4c
and 5b and Supplementary Fig. 2b,c were performed in buffer comprising 25mM
HEPES-NaOH, pH 7.5, 500mM NaCl, 1mM DTT.
Crystallization and structure determination. Screening for crystallization con-
ditions was performed at the High Throughput Crystallization (HTX) laboratory
(EMBL Grenoble, France; Supplementary Methods). Crystals of truncated TAF8–
10 complex (TAF8 residues 25–120 and TAF10 residues 112–212) were reﬁned
manually by mixing equal volumes of protein solution containing 15–25mgml 1
TAF8–10 in 25mM Tris-HCl, 150mM NaCl at pH 7.5 and crystallization solution
containing 1.4M Na/K PO4 at pH 7.6. Crystals grew in space group P3121 with cell
dimensions of a¼ b¼ 51.3 Å and c¼ 144.8 Å. Crystals were cryoprotected by
adding 20% (v/v) glycerol and ﬂash frozen in liquid nitrogen. Diffraction data were
collected at 100 K on beamline PROXIMA 1 using a Pilatus 6M detector (SOLEIL
synchrotron, Gif-sur-Yvette, France) and were integrated and scaled using X-ray
Detector Software (XDS)57. The structure of TAF8–10 was solved by the Sulfur-
SAD method. A partial model could be built into the experimental electron density
map by iterative rounds of density modiﬁcation and automated structure building
using programs Pirate and Buccaneer from the CCP4i suite58. The model was used
to phase a high-resolution data set by molecular replacement using Phaser58,59.
Diffraction data were corrected for anisotropy using the Diffraction Anisotropy
Server (services.mbi.ucla.edu/anisoscale)60 and an isotropic B of  11.99Å2. The
TAF8–10 structure was built and reﬁned using programs Coot61 and Phenix62,
respectively, including TLS parameter and individual B-factor reﬁnement.
Crystals of Importin a1 (residues 60–529) with a synthetic TAF8 NLS peptide
(amino acids 297-PVKKPKIRRKKSLS-310 (Peptide Specialty Laboratory,
Germany) were grown by mixing 2 ml of protein solution containing 8mgml 1
Importin a1/TAF8–NLS in 10mM Tris-HCl, pH 8.0, 150mM NaCl and 1mM
DTT with 1 ml reservoir solution containing 100mM HEPES-NaOH, pH 7.1, 12%
(w/v) polyethylene glycole 3,350 and 200mM L-proline in sitting drop vapour
diffusion plates. Crystals grew in space group P212121 with cell dimensions of
a¼ 54.3 Å, b¼ 77.7 Å and c¼ 128.6 Å. Crystals were cryoprotected by the addition
of 30% (v/v) ethylene glycole and ﬂash frozen in liquid nitrogen. Data sets were
collected at 100K on beamline ID14-1 using an ADSC Quantum Q210 detector
(European Synchrotron Radiation Facility ESRF, Grenoble, France). Diffraction
data were integrated and scaled using XDS57. The structure of Importin a1/TAF8–
NLS was solved by molecular replacement using Importin a1 (PDB ID 3RZ9) as a
search model. The Importin a1/TAF8–NLS structure was built and reﬁned with
Coot61 and Phenix62, respectively, including TLS parameter, occupancy and
individual B-factor reﬁnements.
Surface plasmon resonance. Biosensor experiments were performed at 25 C on
a BIACORE 3000 (Biacore AB, Uppsala). TAF2 ligand was immobilized onto CM5
sensor chips (GE Healthcare) to a level of 2,500 RU using amine-coupling
chemistry. Truncation mutants of TAF8 fused C-terminally to MBP were serially
diluted into running buffer (25mM HEPES-NaOH, pH 7.0, 300mM NaCl, 0.01%
(v/v) NP-40). For association phase, 150 ml of analyte at a concentration of 500 nM
were injected at a ﬂow rate of 25ml min 1 and dissociation phases were monitored
for 200 s by injecting running buffer only. Binding responses were recorded and
responses from referencing sensorgrams were subtracted using BIAevaluation
software (GE Healthcare). Data were globally analysed with the analysis software.
Isothermal titration calorimetry. Calorimetric experiments were conducted in
duplicates with a MicroCal iTC200 instrument (GE Healthcare) at 25 C. Importin
a1 (residues 71–479) and the TAF8 NLS peptide (residues 288-NPYLRPVKKP-
KIRRKKSLS-310) were extensively dialysed against ITC buffer (25mM Tris-HCl
pH 8.0, 150mM NaCl, 1mM b-mercaptoethanol) and used at concentrations of
39mM and 1.5mM, respectively. Protein concentrations were determined by
absorbance spectroscopy at 280 nm with calculated extinction coefﬁcients of
48,930M 1 cm 1 for Importin a1 and 1,490M 1 cm 1 for the peptide. TAF8
peptide (1.5 ml) was injected for 3 s with a spacing of 180 s between injections into
200ml of Importin a1. Heat changes were recorded over 26 injections. Calorimetric
titration data were integrated, corrected for heat of dilution of the TAF8 peptide
alone and analysed using Origin software version 7.0 according to a one-site
binding model. Binding stoichiometry (n), association constant (Ka), binding
enthalpy (DH) and entropy change (DS) were deduced from ﬁtted isotherms by
nonlinear regression. Gibbs free energy difference was calculated using the equa-
tion DG¼DH–TDS.
Pull-down assays. MBP pull-down assays were performed by mixing 10 mg bait
(MBP or MBP–TAF2) with 10 mg prey (TAF8–10, TAF8DC–TAF10, TAF8–
TAF10DN) for 1 h at 4 C in binding buffer (25mM HEPES-NaOH, pH 7.5,
500mM NaCl, 5% (v/v) glycerol, 2mM b-mercaptoethanol). Protein mixtures were
incubated with 20ml Amylose resin (New England Biolabs) for 1.5 h at 4 C. Resin
was washed three times with binding buffer, once with washing buffer (25mM
HEPES-NaOH, pH 7.5, 500mM NaCl, 5% (v/v) glycerol, 2mM b-mercaptoetha-
nol, 0.05% NP-40) and again three times with binding buffer. Proteins were eluted
in 15 ml binding buffer containing 30mM D-maltose and analysed by 4–12% Bis-
Tris NuPAGE (Invitrogen).
Limited proteolysis experiments. The TAF8–10 complex (1mgml 1) was
treated with chymotrypsin at an enzyme-to-protein ratio of 1:10 (w/w). Samples
were taken after 2, 5, 10, 20, 40 and 60min and analysed by SDS–PAGE. To
identify the TAF8–10 core complex, the proteolysed sample was loaded on a
Superdex75 10/300 column (GE Healthcare) before N-terminal sequencing and MS
analysis of comigrating polypeptides.
Peptide arrays. Pepscan libraries of the C-terminal region of TAF8 (residues 105–
310) were immobilized on cellulose membranes via double b-alanine anchors and
assembled using the SPOT technology (AG Molekulare Bibliotheken, Charite´—
Universita¨tsmedizin Berlin, Germany). Overlapping 20-mer peptides of TAF8 were
synthesized by Fmoc (9-ﬂuorenylmethoxycarbonyl) chemistry with an offset of
three amino acids between neighbouring spots. Low-density hexa-Histidine pep-
tides were used as controls. Pepscan membranes were blocked in blocking buffer
(50mM Tris-HCl, pH 7.6, 500mM NaCl, 20% (w/v) sucrose, 3% (w/v) bovine
serum albumin) for 1 h at 4 C, washed with TBS (50mM Tris-HCl, pH 7.6,
500mM NaCl) and incubated for 1.5 h with His-tagged TAF2 (10 mgml 1) in
blocking buffer or with blocking buffer alone. Membranes were incubated with
mouse anti-His monoclonal primary antibody (Sigma-Aldrich, catalogue number
H1029, dilution 1:3,000) and peroxidase-conjugated anti-mouse secondary anti-
body (Sigma-Aldrich, catalogue number A5906, dilution 1:10,000) in blocking
buffer. Membranes were washed three times with TBS between each incubation
step. Luminol solution (Pierce) was added and luminescence detected on a
KODAK 4000MM photoimager. Images were analysed using the Dot Blot Analyzer
tool in ImageJ.
Analytical ultracentrifugation. Sedimentation velocity experiments were per-
formed in a Beckman XL-I analytical ultracentrifuge (Beckman Coulter). The
puriﬁed proteins and protein complexes TAF2, TAF8–10 and TAF2–8–10 were
loaded into sapphire-windowed cells with 12-mm optical path length and spun in
an An-60Ti rotor (Beckman Coulter). Absorbance at 280 nm was measured for
16 h at 42,000 r.p.m. and 10 C. The data were analysed in terms of continuous size-
distribution (c(s)) with the Sedﬁt program63, considering 200 particles with
sedimentation coefﬁcients, s, between 0.1 and 20 S. A partial speciﬁc volume of 0.73
and frictional ratios of 1.4 (TAF2, TAF2–8–10) and 1.6 (TAF8–10) were used. A
regularization procedure with conﬁdence level of 0.68 was applied. Sample
densities and viscosities were determined with Sednterp64 to 1.023 gml 1 and
1.40mPa.s (TAF2, TAF2–8–10) and 1.021 gml 1 and 1.31mPa s (TAF8–10).
Native MS. Puriﬁed TAF2–8–10 complex (30 ml) was buffer exchanged into
500mM ammonium acetate buffer (pH 7.5) using Amicon spin concentrators
(Millipore, 10 kDa MWCO). All MS experiments were performed on a Quadrupole
Time-of-ﬂight (Q-ToF) II mass spectrometer (Waters, Manchester, UK) in the
positive ion mode65. For data acquisition, 2 ml of the sample was injected into the
mass spectrometer with gold-coated capillary needles made in-house using a needle
puller (Harvard Apparatus, Holliston, MA, USA). MS spectra were acquired using
a capillary voltage of 1.7 kV and cone and collision voltages of 100V. Time-of-
ﬂight and analyser pressures were at 5.6 10 6 and 4.2 10 4mbar, respectively.
Data sets were acquired and processed with MassLynx V4.1 software (Waters, UK)
with minimal smoothing and no background subtraction. The recorded mass
spectra were calibrated externally using 100mgml 1 caesium iodide in water.
CLMS analyses. 7TAF complexes were produced as described12. 8TAF complexes
were reconstituted from puriﬁed 7TAF complexes by adding twofold molar excess
of TAF2 and removal of unbound TAF2 by SEC. 7TAF (200 mg) and 8TAF
complexes (200 mg) were crosslinked by BS3 (Bis-sulfosuccinimidyl suberate,
Thermo Scientiﬁc) at complex/BS3 ratio of 1:5 (w/w) in crosslinking buffer (25mM
HEPES-NaOH, pH 7.6, 150mM NaCl, 1mM DTT) for 2 h on ice. The reaction was
quenched by adding saturated ammonium bicarbonate solution followed by
incubation on ice (45min). Crosslinked samples were concentrated using spin
concentrators (Millipore) and separated on NuPAGE 3–8% Tris-Acetate gels run
in Tris-Acetate SDS running buffer (Invitrogen). Bands corresponding to
crosslinked complexes were excised, crosslinked complex proteins reduced,
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7011 ARTICLE
NATURE COMMUNICATIONS | 6:6011 | DOI: 10.1038/ncomms7011 | www.nature.com/naturecommunications 11
& 2015 Macmillan Publishers Limited. All rights reserved.
alkylated and trypsin digested following standard procedures. Crosslinked peptides
were fractionated using SCX-StageTips following published protocols for linear
peptides and desalted using C18 StageTips41.
Mass spectrometry. Peptides were analysed on an LTQ Orbitrap Velos mass
spectrometer coupled with an UltiMate 3000 Rapid Seperation LC system (Thermo
Fisher Scientiﬁc). The column was packed into a spray emitter (75-mm inner
diameter, 8-mm opening, 250-mm length; New Objectives) with C18 material
(ReproSil-Pur C18-AQ 3 mm; Dr Maisch, Ammerbuch-Entringen, Germany) using
an air pressure pump (Proxeon Biosystems). Mobile phase A consisted of water
and 0.1% formic acid. Mobile phase B consisted of 80% acetonitrile and 0.1%
formic acid. Peptides were loaded onto the column with 2% B at 500 nlmin 1 ﬂow
rate and eluted at 300 nlmin 1 ﬂow rate in two steps: linear increase from 2% B to
40% B in 139min; then increase from 40 to 95% B in 11min. The eluted peptides
were directly sprayed into the mass spectrometer. Peptides were analysed using a
high/high strategy: both MS spectra and MS2 spectra were acquired in the
Orbitrap. MS spectra were recorded at 100,000 resolution. The eight highest
intensity peaks with a charge state of three or higher were selected in each cycle for
ion trap fragmentation. Fragments were produced using CID with 35% normalized
collision energy and detected by the Orbitrap at 7,500 resolution. Dynamic
exclusion was set to 90s and repeat count was 1.
Data processing. The mass spectrometric raw ﬁles were processed into peak lists
using MaxQuant (version 1.3.0.5) (ref. 41) at default parameters except for ‘top
MS/MS peaks per 100Da’ being set to 100. Search was conducted against TAF
complex sequences using Xi software (version 1.3.355). Search parameters were MS
accuracy, 6 p.p.m.; MS/MS accuracy, 20 p.p.m.; enzyme, trypsin; crosslinker, BS3
(including BS3 modiﬁcation); max. missed cleavages, 4; ﬁxed modiﬁcation,
carbamidomethylation on cysteine; variable modiﬁcations, oxidation on
methionine; crosslinkable amino acids, N terminus, lysine, serine, tyrosine and
threonine; fragments, b and y ions with loss of H2O, NH3 and CH3SOH. The data
have been validated by 5% FDR with manual validation. UniProt protein accession
numbers of the protein sequences used to search the database were as follows:
TAF2 (Q6P1X5-1; with a sequence variation R785G; European Nucleotide Archive
AAC68502.1), TAF4 (O00268-1), TAF5 (Q15542-1), TAF6 (P49848-1), TAF8
(Q7Z7C8-1), TAF9 (Q16594-1), TAF10 (Q12962-1), and TAF12 (Q16514-1).
Crosslinks observed in artiﬁcially introduced sequences (for example, TEV cleavage
sites in polyproteins or puriﬁcation tags) were not included in the search. The MS
data were deposited to the ProteomeXchange Consortium66 via the PRIDE partner
repository with the data set identiﬁer PXD001454 (http://www.proteomexchange.org).
Antibody production and puriﬁcation. TAF2 antibodies were generated by
immunizing rabbits with puriﬁed TAF2. Antibody puriﬁcation was done as
described67 with the following modiﬁcations: 2mg of recombinant full-length
human TAF2 were ﬁxed on 400 ml Afﬁ-Gel 10/15 beads (Bio-Rad) for 2 h at 4 C
with gentle agitation in PBS. Free active esters were blocked with 1M ethanolamine
HCl (pH 8) solution for 1 h at 4 C under gentle agitation. The TAF2-bound gel
was transferred to a column and washed four times with 10 volumes of PBS. Ten
ml of rabbit polyclonal antibody sera raised against human TAF2 was applied twice
and the column was washed with 10ml of PBS before elution. Bound antibodies
were eluted with 0.1M glycine (pH 2.5) buffer. Fractions of puriﬁed antibody
(500 ml) were collected and quickly neutralized by adding 50 ml 2M Tris-HCl (pH
8.8) buffer.
Protein extract preparations and immunprecipitation and MudPIT analyses.
HeLa cell nuclear extract (NE) preparations and immunoprecipitations were done
as described68 with minor modiﬁcations. Supernatant containing the cytoplasm
was precipitated by adding stepwise 0.3 gml 1 ammonium sulfate under agitation
(4 C, 30min). Precipitated proteins were collected by centrifugation (30,000g, 4 C,
20min), resuspended and dialysed overnight.
Immunoprecipitated proteins were eluted from the protein G columns with
0.1M glycine (pH 2.5) and quickly neutralized with 2M Tris-HCl (pH 8.8). For
MudPIT69 analyses, protein mixtures were trichloroacetic acid precipitated, urea
denaturated, reduced, alkylated and digested with endoproteinase Lys-C followed
by modiﬁed trypsin digestion. Peptide mixtures were loaded onto a triphasic 100-
mm diameter fused silica microcapillary column70. Loaded columns were placed
in-line with a Quaternary Dionex Ultimate 3000 HPLC pump and a LTQ Velos
linear ion trap mass spectrometer equipped with a nano-LC electrospray ionization
source (Thermo Fischer Scientiﬁc). A fully automated 12-steps MudPIT run was
performed during which each full MS scan (from 300 to 1,700m/z range) was
followed by 20 MS/MS events using data-dependent acquisition69. Proteins were
identiﬁed by database searching using SEQUEST with ThermoProteome
Discoverer 1.4 (Thermo Fischer Scientiﬁc)71. Tandem mass spectra were searched
against a human protein sequence database (from the Homo sapiens 2013-04-03
Swissprot release). In all searches, cysteine residues were considered to be fully
carboxyamidomethylated (þ 57Da statically added) and methionine to be oxidized
(þ 16Da dynamically added). Relative protein abundance for each protein in a
given sample was estimated by normalized spectral abundance factor72.
Normalized spectral abundance factor values were calculated from the spectral
counts of each identiﬁed protein. Larger proteins tend to contribute more peptide/
spectra and, therefore, spectral counts were divided by protein length to provide a
spectral abundance factor (SAF). SAF values were then normalized against the sum
of all SAF values in the corresponding run allowing the comparison of protein
levels across different runs. The MS proteomics data were deposited to the
ProteomeXchange Consortium66 via the PRIDE partner repository with the data
set identiﬁer PXD001427.
Immunoﬂuorescence. Indirect immunoﬂuorescence tests were performed as
described30 with the following modiﬁcations: cells were ﬁxed with 4%
paraformaldehyde for 15min at room temperature (RT) and then permeabilized
with 0.1% Triton-X100 for 20min at RT, incubated for 1 h at RT with either an
anti-TAF2 (rabbit polyclonal serum; 3038; described above; diluted 1:100)þ anti-
TAF8 (mouse monoclonal antibody (mAb) 1FR-1B6 (ref. 6); diluted 1:1,000) or
anti-TAF2þ anti-TAF10 (mAb 6TA-2B11 (ref. 6); diluted 1:1,000) antibody mix
followed by incubation (RT, 1 h) with secondary antibody mix including Alexa488-
labelled goat anti-rabbit mAb (Life Technologies, catalogue number A-11034,
diluted 1:3,000; detects anti-TAF2) and Alexa568-labelled goat anti-mouse mAb
(Life Technologies, catalogue number A-11004, diluted 1:3,000; detects either anti-
TAF8 or anti-TAF10). As negative control, cells were incubated with secondary
antibodies only to quantify background signal. Cells were mounted using
Vectashield mounting medium with DAPI (Vector laboratories Inc.). Images were
analysed on a Leica wideﬁeld ﬂuorescence microscope (DMRXA2) equipped with a
CoolSnap HQ camera ( 63 or  100 magniﬁcation). Fluorescence intensity
measurements in the cell cytoplasm were performed using Fiji software; intensity
values were normalized to background signals.
siRNA transfection. siRNAs targeting TAF8 (ON-TARGETplus SMARTpool
siRNA J-015912-20, J015912-19, J015912-18, J015912-17; Dharmacon; Thermo-
Sientiﬁc) and non-targeting control (D-001810-10-20) were transfected into HeLa
cells using Lipofectamine 2000 transfection reagent (Invitrogen). Cells were ﬁxed
for immunoﬂuorescence experiments 48 h after transfection.
Electron microscopy. Specimen preparation. 8TAF sample was stabilized by mild
glutaraldehyde crosslinking (GraFix73). Two-hundred ml puriﬁed 8TAF complexes
were loaded on a 4-ml centrifugation tube containing a 10 to 30% glycerol and a 0
to 0.15% glutaraldehyde gradient followed by centrifugation (34,000 r.p.m., 18 h,
4 C) with a SW60 rotor (Beckman Coulter). Fractions containing stabilized sample
were deposited onto a buffer exchange column (Zeba spin desalting columns,
Pierce) to remove excess glycerol. Specimen was adsorbed onto a thin layer of
carbon deposited on an electron microscopy grid and negatively stained for 45 s
with 2% of uranyl acetate. Particles were imaged using a transmission electron
microscope (Tecnai F20 G2, FEI) equipped with a ﬁeld emission gun operating
at 200 kV. Images were recorded under low-dose condition (total dose of
40–50 eÅ 2) on a 2,048 2,048 CCD camera (Ultrascan 1000, Gatan Inc.,
Pleasanton) at a magniﬁcation of 50,000 resulting in a pixel spacing on the
specimen of 0.21 nm.
Random conical tilt reconstructions. The initial reference volumes were obtained
by random conical tilt using XMIPP74 and IMAGIC75 software packages. Two
consecutive images of the same area were taken at 45 and 0 tilt angles under low-
dose conditions. A total of 1,546 tilt pairs were selected manually using XMIPP.
Untilted images were aligned using iteratively reﬁned two-dimensional class
averages as references and multivariance statistical analysis and Hierarchical
Ascendant Classiﬁcation for clustering into 50 class averages with IMAGIC. Fifty
volumes calculated from two-dimensional classes were aligned, clustered and
averaged using XMIPP MLtomo to compensate for the missing cone, resulting in
ﬁve random conical tilt (RCT) reconstructions.
Structure reﬁnement. The best volume was used as reference for reﬁnement
cycles using a data set of 35,145 untilted molecular images windowed with the
Boxer application of the EMAN2 software package76 and coarsened by two
resulting in a pixel spacing of 4.2 Å. Image sorting was found necessary to select the
most homogeneous particles since part of the structure was ﬂexible and prevented
convergence. Sorting was performed by using ﬁrst XMIPP then subsequently the
RELION software package77. Final 3D reconstruction was performed in RELION
with 2,361 sorted particles resutling in a structure with 37Å resolution as estimated
by the 0.5 Fourier Shell Correlation criteria. Images were prepared using Chimera
software (http://www.cgl.ucsf.edu/chimera).
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